查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933338

外分泌胰臟功能不全治疗市场规模、占有率、成长、全球产业分析：依类型、应用、区域洞察、预测（2026-2034 年）

Exocrine Pancreatic Insufficiency Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 128 Pages | 商品交期: 请询问到货日

价格

外分泌胰臟功能不全 (EPI) 治疗市场成长因子

由于胰臟疾病盛行率的上升以及人们对消化系统健康意识的增强，全球外分泌胰臟功能不全 (EPI) 治疗市场正经历稳定成长。外分泌胰臟功能不全是一种以胰臟外分泌酶缺乏为特征的疾病，会导致消化不良和营养吸收不良。由于症状通常不明显且容易被忽视，因此诊断通常需要进行专门的检查，包括血液检查、粪便检查和胰腺功能评估。 2025年，该市场价值为24.3亿美元，预计2026年将成长至25.5亿美元，到2034年将达到35.1亿美元。这意味着2026年至2034年的复合年增长率（CAGR）为4.06%。北美在2025年以3.85%的市占率领先，这得益于较高的认知度、先进疗法的快速应用以及强大的研发基础设施。

市场驱动因素与趋势

认知度提升与治疗创新

外分泌胰臟炎（EPI）治疗市场的成长是由人们对该疾病及其全身影响的认知度提高所驱动的。急性胰臟炎、囊性纤维化和胰臟肿瘤是导致EPI盛行率显着增加的重要因素。例如，2019 年 10 月，AzurRx BioPharma 开始为患者使用 MS1819-SD，这是一种用于治疗外分泌胰腺功能不全 (EPI) 的创新疗法。人们对 EPI 的认识不断提高，推动了胰酶替代疗法 (PERT) 等疗法的研发和应用，而 PERT 一直是传统上最有效的治疗方法。

相关疾病的成长趋势

包括自体免疫性胰臟炎和施瓦赫曼-戴蒙德症候群在内的胃肠道和胰臟疾病的盛行率直接影响 EPI 的发生率。这推动了治疗研发领域的持续创新，提高了疗效和安全性，并促进了全球市场的扩张。

技术与临床进展

诊断工具和治疗方案的进步，以及研发投入的增加，正在推动治疗方案的改进。由于其高效性、有效性和已确立的临床疗效，胰酶替代疗法 (PERT) 占市场主导地位，预计到 2025 年将创造 21.2 亿美元的收入。

市场区隔

依疗法

  • 胰酵素替代疗法 (PERT)：由于其临床疗效和广泛应用，PERT 占市场主导地位，并以最高的复合年增长率 (CAGR) 成长。
  • 营养疗法：支持患者管理，但市占率较小，成长率较低。外分泌性胰臟功能不全 (EPI) 患者的营养不良会导致併发症和死亡率增加，凸显了该细分市场的重要性。

依分销管道

  • 医院药局：处方通常在临床诊断后开立，因此预计将保持最大的市场占有率（2025 年为 67.9%）。
  • 零售药局和药局：便利性以及与线上药局日益紧密的整合将促进二次成长。

区域分析

预计北美市场将在2025年以18.9亿美元的规模引领市场，并在2026年增长至19.8亿美元，这主要得益于强劲的研发投入、较高的治疗普及率以及疾病认知度的提高。光是美国市场预计到2026年就将达到16.9亿美元。

亚太地区预计将实现最快成长，这主要得益于可支配收入的增加、先进疗法的普及以及公众意识的提高。主要市场包括日本（2026年9000万美元）、中国（2026年6000万美元）和印度（2026年3000万美元）。

由于低渗透率地区存在发展机遇，预计欧洲市场将维持稳定成长。由于公众意识的提高和治疗途径的改善，英国（2026年预计为5000万美元）和德国（2026年预计为7000万美元）等国家的市场正在扩张。

由于市场渗透率低且医疗基础设施尚在发展中，预计拉丁美洲以及中东和非洲地区的市场成长速度将放缓。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇

第四章：关键考虑因素

  • 与外分泌胰臟功能不全相关的主要疾病的盛行率
  • 研发管线分析
  • 近期产业趋势，包括併购、合作与收购
  • 监理环境
  • 新产品发布

第五章：全球外分泌胰臟功能不全治疗市场分析、洞察与预测 2021-2034

  • 主要发现/摘要
  • 依疗法划分的市场分析、见解和预测
    • 胰酵素替代疗法 (PERT)
      • CREON
      • ZenPep
      • 其他
    • 营养疗法
  • 依分销管道划分的市场分析、洞察与预测
    • 医院药房
    • 零售药局和药局
    • 其他
  • 依国家/地区划分的市场分析、洞察与预测
    • 北美
    • 欧洲
    • 亚太地区
    • 世界其他地区

第六章 北美外分泌胰臟功能不全治疗市场分析、洞察与预测 2021-2034

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲外分泌胰臟功能不全治疗市场分析、洞察与预测，2021-2034

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区

第八章：亚太地区外分泌胰臟功能不全治疗市场分析、洞察与预测，2021-2034

  • 依国家/地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 亚太其他地区

第九章：世界其他地区外分泌胰臟功能不全治疗市场分析、洞察与预测（2021-2034）

第十章：竞争分析

  • 主要行业趋势
  • 全球市占率分析（2025）
  • 竞争概览
  • 竞争分析
  • 公司简介
    • AbbVie Inc.
    • Janssen Pharmaceuticals, Inc.
    • Allergan
    • AzurRx
    • CHIESI Farmaceutici S.p.A.
    • Other Prominent Players
Product Code: FBI100652

Growth Factors of exocrine pancreatic insufficiency (EPI) therapeutics Market

The global exocrine pancreatic insufficiency (EPI) therapeutics market is witnessing steady growth due to the rising prevalence of pancreatic disorders and increasing awareness of gastrointestinal health. Exocrine pancreatic insufficiency is a condition marked by the deficiency of exocrine pancreatic enzymes, resulting in maldigestion and nutrient malabsorption. Diagnosis often involves specialized tests such as blood, stool, and pancreatic function assessments, as symptoms are frequently under-detected. In 2025, the market was valued at USD 2.43 billion, projected to grow to USD 2.55 billion in 2026, and expected to reach USD 3.51 billion by 2034, reflecting a CAGR of 4.06% from 2026 to 2034. North America dominated the market in 2025 with a 3.85% share, supported by high awareness, rapid adoption of advanced therapies, and robust R&D infrastructure.

Market Drivers and Trends

Rising Awareness and Therapeutic Innovations

The growth of the EPI therapeutics market is fueled by increased awareness of the disorder and its impact on overall health. Acute pancreatitis, cystic fibrosis, and pancreatic tumors are major contributors to EPI prevalence. For instance, in October 2019, AzurRx BioPharma dosed patients with MS1819-SD, an innovative therapeutic for EPI. The rising recognition of EPI has propelled the development and adoption of therapies such as Pancreatic Enzyme Replacement Therapy (PERT), which remains the conventional and most effective treatment.

Increasing Prevalence of Associated Disorders

The prevalence of gastrointestinal and pancreatic disorders, including autoimmune pancreatitis and Shwachman-Diamond syndrome, directly influences EPI incidence. This has led to continued R&D innovation in therapeutics, enhancing efficacy and safety profiles, which drives market expansion globally.

Technological and Clinical Advancements

Advancements in diagnostic tools and treatment regimens, coupled with rising R&D investments, have facilitated improved therapeutic options. PERT, projected to generate USD 2.12 billion in revenue by 2025, dominates the market due to its efficiency, potency, and established clinical outcomes.

Market Segmentation

By Therapy

  • Pancreatic Enzyme Replacement Therapy (PERT): Dominates the market, growing at the highest CAGR due to its clinical effectiveness and broad adoption.
  • Nutritional Therapy: Supports patient management but holds a smaller share and lower growth rate. Poor nutrition in EPI patients can lead to increased complications and mortality, highlighting the importance of this segment.

By Distribution Channel

  • Hospital Pharmacies: Expected to hold the largest share (67.9% in 2025) as prescriptions are typically issued after clinical diagnosis.
  • Retail Pharmacies & Drug Stores: Offer convenience and increasing online pharmacy integration, supporting secondary growth.

Regional Analysis

North America dominated the market with USD 1.89 billion in 2025, rising to USD 1.98 billion in 2026, driven by strong R&D, high treatment adoption, and increasing disease awareness. The U.S. market alone is projected to reach USD 1.69 billion by 2026.

Asia Pacific is poised for the fastest growth due to increasing disposable incomes, adoption of advanced therapeutics, and better awareness. Key markets include Japan (USD 0.09 billion in 2026), China (USD 0.06 billion in 2026), and India (USD 0.03 billion in 2026).

Europe is growing steadily with opportunities in under-penetrated regions. Countries such as the U.K. (USD 0.05 billion in 2026) and Germany (USD 0.07 billion in 2026) are expanding due to rising awareness and improved therapeutic access.

Latin America and Middle East & Africa are expected to experience moderate growth due to under-penetration and emerging healthcare infrastructure.

Competitive Landscape

The market is concentrated with major players such as AbbVie Inc., Janssen Pharmaceuticals, and Allergan, leveraging broad product portfolios and global presence. Smaller and emerging players, including AzurRx and CHIESI Farmaceutici S.p.A., contribute through innovation and new therapeutic pipelines. AbbVie's 2024 gastroenterology portfolio update at the ECCO Congress highlights ongoing R&D commitment to EPI and related disorders.

Conclusion

The global exocrine pancreatic insufficiency therapeutics market is set to expand from USD 2.43 billion in 2025 to USD 3.51 billion by 2034, at a CAGR of 4.06%. Market growth is primarily driven by increasing prevalence of associated disorders, rising awareness, innovations in therapeutics such as PERT, and robust R&D investments. North America remains the dominant region, while Asia Pacific offers the fastest growth potential due to rising healthcare adoption and disposable incomes. Despite challenges like under-penetration in certain regions and ongoing regulatory requirements, the EPI therapeutics market is positioned for sustained growth over the forecast period.

Segmentation By Therapy

  • Pancreatic Enzyme Replacement Therapy (PERT)
    • Creon
    • Zenpep
    • Others
  • Nutritional Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, and Rest of Asia Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Major Disorders Associated With Exocrine Pancreatic Insufficiency
  • 4.2. Pipeline Analysis
  • 4.3. Recent Industry Developments Such as Mergers, Partnerships & Acquisitions
  • 4.4. Regulatory Scenario
  • 4.5. New Product Launches

5. Global Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Therapy
    • 5.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 5.2.1.1. Creon
      • 5.2.1.2. Zenpep
      • 5.2.1.3. Others
    • 5.2.2. Nutritional Therapy
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies & Drug Stores
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Country
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Therapy
    • 6.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 6.2.1.1. Creon
      • 6.2.1.2. Zenpep
      • 6.2.1.3. Others
    • 6.2.2. Nutritional Therapy
  • 6.3. Market Analysis - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies & Drug Stores
    • 6.3.3. Others
  • 6.4. Market Analysis - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Therapy
    • 7.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 7.2.1.1. Creon
      • 7.2.1.2. Zenpep
      • 7.2.1.3. Others
    • 7.2.2. Nutritional Therapy
  • 7.3. Market Analysis - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies & Drug Stores
    • 7.3.3. Others
  • 7.4. Market Analysis - By Country
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Therapy
    • 8.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 8.2.1.1. Creon
      • 8.2.1.2. Zenpep
      • 8.2.1.3. Others
    • 8.2.2. Nutritional Therapy
  • 8.3. Market Analysis - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies & Drug Stores
    • 8.3.3. Others
  • 8.4. Market Analysis - By Country
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Rest of Asia Pacific

9. Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Therapy
    • 9.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
      • 9.2.1.1. Creon
      • 9.2.1.2. Zenpep
      • 9.2.1.3. Others
    • 9.2.2. Nutritional Therapy
  • 9.3. Market Analysis - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies & Drug Stores
    • 9.3.3. Others
  • 9.4. Market Analysis - By Country

10. Competitive Analysis

  • 10.1. Key Industry Developments
  • 10.2. Global Market Share Analysis (2025)
  • 10.3. Competition Dashboard
  • 10.4. Comparative Analysis - Major Players
  • 10.5. Company Profiles
    • 10.5.1. AbbVie Inc.
      • 10.5.1.1. Overview,
      • 10.5.1.2. Products & services,
      • 10.5.1.3. SWOT analysis,
      • 10.5.1.4. Recent developments,
      • 10.5.1.5. strategies,
      • 10.5.1.6. financials (based on availability)
    • 10.5.2. Janssen Pharmaceuticals, Inc.
      • 10.5.2.1. Overview,
      • 10.5.2.2. Products & services,
      • 10.5.2.3. SWOT analysis,
      • 10.5.2.4. Recent developments,
      • 10.5.2.5. strategies,
      • 10.5.2.6. financials (based on availability)
    • 10.5.3. Allergan
      • 10.5.3.1. Overview,
      • 10.5.3.2. Products & services,
      • 10.5.3.3. SWOT analysis,
      • 10.5.3.4. Recent developments,
      • 10.5.3.5. strategies,
      • 10.5.3.6. financials (based on availability)
    • 10.5.4. AzurRx
      • 10.5.4.1. Overview,
      • 10.5.4.2. Products & services,
      • 10.5.4.3. SWOT analysis,
      • 10.5.4.4. Recent developments,
      • 10.5.4.5. strategies,
      • 10.5.4.6. financials (based on availability)
    • 10.5.5. CHIESI Farmaceutici S.p.A.
      • 10.5.5.1. Overview,
      • 10.5.5.2. Products & services,
      • 10.5.5.3. SWOT analysis,
      • 10.5.5.4. Recent developments,
      • 10.5.5.5. strategies,
      • 10.5.5.6. financials (based on availability)
    • 10.5.6. Other Prominent Players
      • 10.5.6.1. Overview,
      • 10.5.6.2. Products & services,
      • 10.5.6.3. SWOT analysis,
      • 10.5.6.4. Recent developments,
      • 10.5.6.5. strategies,
      • 10.5.6.6. financials (based on availability)

List of Tables

  • Table 1: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 2: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 3: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 6: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 7: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 10: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 11: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 14: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 15: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Product, 2021-2034
  • Table 18: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Table 19: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Exocrine Pancreatic Insufficiency Therapeutics Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Pancreatic Enzyme Replacement Therapy (PERT), 2021-2034
  • Figure 4: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Nutritional Therapy, 2021-2034
  • Figure 5: Global Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 7: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Retail Pharmacies & Drug Stores, 2021-2034
  • Figure 8: Global Exocrine Pancreatic Insufficiency Therapeutics Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 9: Global Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 10: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 11: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
  • Figure 12: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 13: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 14: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 15: North America Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), By Country, 2025
  • Figure 16: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 17: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
  • Figure 18: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 25: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 26: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 27: Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 28: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Product, 2025 & 2034
  • Figure 29: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Product, 2025
  • Figure 30: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 31: Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 32: Global Exocrine Pancreatic Insufficiency Therapeutics Market Share (%), By Company, 2025